Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Whitemarsh, Regina Clare Meyer ^a   Tepp, William Howard ^a   Johnson, Eric Arthur ^a   Pellett, Sabine ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A1; BOTULINUM TOXIN A2; BOTULINUM TOXIN A3; BOTULINUM TOXIN A4; BOTULINUM TOXIN A5; BOTULINUM TOXIN E; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; NONHUMAN; PROTEIN CLEAVAGE; RAT; SPINAL CORD NERVE CELL;

ANIMALS; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; INTRACELLULAR SPACE; NEURONS; RATS; SPINAL CORD; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TIME FACTORS;

EID: 84896383439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090252     Document Type: Article

References (42)

1. Smith LD, Sugiyama H (1988) Botulism: The Organism, Its Toxins, The Disease. Springfield, IL: Charles C. Thomas.
2. Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol. England. pp. 325-336.
3. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiological reviews 56: 80-99.
4. Gimenez DF, Gimenez JA (1995) The typing of botulinal neurotoxins. International journal of food microbiology 27: 1-9.
5. Barash JR, Arnon SS (2014) A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. J Infect Dis 209: 183-191.
6. Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2014) Molecular characterization of a novel botulinum neurotoxin type h gene. J Infect Dis 209: 192-202.
7. Hill KK, Smith TJ (2013) Genetic diversity Within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364: 1-20.
8. Jankovic J, Brin MF (1997) Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl 6: S129-145. (Pubitemid 128753042)
9. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, et al. (2011) Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS letters 585: 199-206.
10. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, et al. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. The Journal of biological chemistry 278: 1363-1371. (Pubitemid 36790822)
11. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS letters 456: 137-142. (Pubitemid 29339056)
12. Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139: 629-637.
13. Adler M, Keller JE, Sheridan RE, Deshpande SS (2001) Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 39: 233-243. (Pubitemid 30649070)
14. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neuroscience letters 256: 135-138. (Pubitemid 28546908)
15. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 96: 3200-3205. (Pubitemid 29148868)
16. Dineen SS, Bradshaw M, Johnson EA (2003) Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr Microbiol 46: 345-352. (Pubitemid 36919722)
17. Willems A, East AK, Lawson PA, Collins MD (1993) Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Research in microbiology 144: 547-556.
18. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, et al. (2007) Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. Journal of Bacteriology 189: 818-832. (Pubitemid 46183856)
19. Dover N, Barash JR, Arnon SS (2009) Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. Journal of clinical microbiology 47: 2349-2350.
20. Luquez C, Raphael BH, Maslanka SE (2009) Neurotoxin gene clusters in Clostridium botulinum type Ab strains. Appl Environ Microbiol. United States. pp. 6094-6101.
21. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, et al. (2010) Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS letters. 585:199-206.
22. Malizio CJ, Goodnough MC, Johnson EA (2000) Purification of Clostridium botulinum type A neurotoxin. Methods in molecular biology (Clifton, NJ) 145: 27-39.
23. Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA (2010) Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Applied and Environmental Microbiology 76: 40-47.
24. Tepp WH, Lin G, Johnson EA (2012) Purification and characterization of a novel subtype a3 botulinum neurotoxin. Applied and Environmental Microbiology 78: 3108-3113.
25. Jacobson MJ, Lin G, Tepp W, Dupuy J, Stenmark P, et al. (2011) Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Applied and Environmental Microbiology 77: 4217-4222.
26. Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, et al. (2010) Construction of a Nontoxigenic Clostridium botulinum Strain for Food Challenge Studies. Applied and Environmental Microbiology 76: 387-393.
27. Heap JT, Pennington OJ, Cartman ST, Minton NP (2009) A modular system for Clostridium shuttle plasmids. J Microbiol Methods 78: 79-85.
28. Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, et al. (2013) Characterization of botulinum neurotoxin a subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun 81: 3894-3902.
29. Schantz EJ and Kautter DA (1978) Standardized assay for Clostridium botulinum toxins. Journal of the Association of Official Analytical Chemists 61: 96-99.
30. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA (2007) A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS letters 581: 4803-4808. (Pubitemid 47531746)
31. Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, et al. (2012) Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicological sciences: an official journal of the Society of Toxicology 126: 426-435.
32. Whelchel DD, Brehmer TM, Brooks PM, Darragh N, Coffield JA (2004) Molecular targets of botulinum toxin at the mammalian neuromuscular junction. Movement disorders: official journal of the Movement Disorder Society 19 Suppl 8: S7-S16.
33. Hassan SM, Jennekens FG, Wieneke G, Veldman H (1994) Elimination of superfluous neuromuscular junctions in rat calf muscles recovering from botulinum toxin-induced paralysis. Muscle Nerve 17: 623-631. (Pubitemid 24157386)
34. Tian WH, Festoff BW, Blot S, Diaz J, Hantai D (1995) Synaptic transmission blockade increases plasminogen activator activity in mouse skeletal muscle poisoned with botulinum toxin type A. Synapse 20: 24-32.
35. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR (2004) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19 Suppl 8: S23-34. (Pubitemid 38967508)
36. Dolly J, Lisk G, Foran P (2002) Insights into the extended duration of neuroparalysis by Botulinum Neurotoxin A relative to the other shorter-actin serotypes: differences between motor nerve terminals and cultured neurons. In: Brin M, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins. pp. 91-102.
37. Meunier FA, Lisk G, Sesardic D, Dolly JO (2003) Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 22: 454-466. (Pubitemid 36513569)
38. Fernandez-Salas E, Steward LE, Ho H, Garay PE, Sun SW, et al. (2004) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 101: 3208-3213. (Pubitemid 38327759)
39. Chakraborty S, Nazmi A, Dutta K, Basu A (2010) Neurons under viral attack: victims or warriors? Neurochem Int 56: 727-735.
40. Patterson-Curtis SI, Johnson EA (1989) Regulation of neurotoxin and protease formation in Clostridium botulinum Okra B and Hall A by arginine. Appl Environ Microbiol 55: 1544-1548. (Pubitemid 19155079)
41. DasGupta BR (2006) Botulinum neurotoxins: perspective on their existence and as polyproteins harboring viral proteases. J Gen Appl Microbiol 52: 1-8.
42. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, et al. (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 107: 16554-16559.